Up­sized of­fer­ing de­liv­ers $100M pay­off to ar­genx as an­oth­er biotech joins the IPO pa­rade

The Dutch an­ti­body shop ar­genx is the lat­est biotech to join the grow­ing IPO pa­rade on Nas­daq.

The biotech raised $100 mil­lion on the sale of 5.9 mil­lion shares at $17 each. And that re­flects an in­crease of more than 2 mil­lion shares over what the com­pa­ny had ini­tial­ly planned to of­fer.

Ar­genx will trade un­der the ARGX sym­bol and CEO Tim Van Hauw­er­meiren gets to ring the open­ing bell to­day to cel­e­brate the IPO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.